Keywords: Merck & Co, Vytorin, Zetia, USA, FDA, Cholesterol, CKD

US FDA mixed views on Vytorin and Zetia

Article | 26 January 2012

Print This

US drug giant Merck & Co (NYSE: MRK) yesterday received Food and Drug Administration approval to update the label for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in